| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
,
W C J Hop4,
J Prins5,
A F Kuipers6,
H R Pasma7,
C A J Hensing8,
E C Creutzberg1 for the COSMIC (COPD and Seretide: a Multi-Center Intervention and Characterization) Study Group
1 Department of Respiratory Medicine, University Hospital Maastricht, The Netherlands
2 Department of Respiratory Medicine, University Hospital Groningen, The Netherlands
3 GlaxoSmithKline BV, Zeist, The Netherlands
4 Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
5 Department of Respiratory Medicine, West-Fries Gasthuis Hoorn, The Netherlands
6 Department of Respiratory Medicine, Isala Clinics Zwolle, The Netherlands
7 Department of Respiratory Medicine, Medical Center Leeuwarden, The Netherlands
8 Department of Respiratory Medicine, Diaconessenhuis Meppel The Netherlands
Correspondence to:
Correspondence to:
Dr E C Creutzberg
University Hospital Maastricht, Department of Respiratory Medicine, P O Box 5800, 6202 AZ Maastricht, The Netherlands; evacreutzberg{at}proteion.nl
Background: Guidelines recommend inhaled corticosteroids (ICS) as maintenance treatment for patients with chronic obstructive pulmonary disease (COPD) with a post-bronchodilator forced expiratory volume in 1 second (FEV1) <50% predicted and frequent exacerbations, although they have only a small preventive effect on the accelerated decline in lung function. Combined treatment with ICS and long acting ß2 agonists (LABA) may provide benefit to the stability of COPD, but it is unknown if withdrawal of ICS will result in disease deterioration.
Methods: The effects of 1 year withdrawal of the ICS fluticasone propionate (FP) after a 3 month run-in treatment period with FP combined with the LABA salmeterol (S) (500 µg FP + 50 µg S twice daily; SFC) were investigated in patients with COPD in a randomised, double blind study. 497 patients were enrolled from 39 centres throughout the Netherlands; 373 were randomised and 293 completed the study.
Results: The drop out rate after randomisation was similar in the two groups. Withdrawal of FP resulted in a sustained decrease in FEV1: mean (SE) change from baseline –4.4 (0.9)% (S) v –0.1 (0.9)% (SFC); adjusted difference 4.1 (95% CI 1.6 to 6.6) percentage points (p<0.001). Corresponding figures for the FEV1/FVC ratio were –3.7 (0.8)% (S) v 0.0 (0.8)% (SFC) (p = 0.002). The annual moderate to severe exacerbation rate was 1.6 and 1.3 in the S and SFC groups, respectively (adjusted rate ratio 1.2; 95% CI 0.9 to 1.5; p = 0.15). The mean annual incidence rate of mild exacerbations was 1.3 (S) v 0.6 (SFC), p = 0.020. An immediate and sustained increase in dyspnoea score (scale 0–4; mean difference between groups 0.17 (0.04), p<0.001) and in the percentage of disturbed nights (6 (2) percentage points, p<0.001) occurred after withdrawal of fluticasone.
Conclusions: Withdrawal of FP in COPD patients using SFC resulted in acute and persistent deterioration in lung function and dyspnoea and in an increase in mild exacerbations and percentage of disturbed nights. This study clearly indicates a key role for ICS in the management of COPD as their discontinuation leads to disease deterioration, even under treatment with a LABA.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LABA, long acting ß2 agonists; MEF50, maximal expiratory flow at 50% of FVC; PEF, peak expiratory flow
Keywords: chronic obstructive pulmonary disease; exacerbations; inhaled corticosteroids; lung function; symptoms
Relevant Article
Thorax 2005 60: 441.
This article has been cited by other articles:
|
|
 |
|
  E. Marchand Treatment Step Down Should Be Avoided at Entry in COPD Therapeutic Trials Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 105 - 106. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Braganza, R. Chaudhuri, and N. C. Thomson Review: Treating patients with respiratory disease who smoke Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 95 - 107. [Abstract] [PDF]
|
|
|
|
 |
|
 K. H. Groenewegen, D. S. Postma, W. C. J. Hop, P. L. M. L. Wielders, N. J. J. Schlosser, E. F. M. Wouters, and for the COSMIC Study Group Increased Systemic Inflammation Is a Risk Factor for COPD Exacerbations Chest, February 1, 2008; 133(2): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S D Aaron, D Fergusson, G B Marks, S Suissa, K L Vandemheen, S Doucette, F Maltais, J F Bourbeau, R S Goldstein, M Balter, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials Thorax, February 1, 2008; 63(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Brown Tiotropium in Combination with Placebo, Salmeterol, or Fluticasone Salmeterol for Chronic Obstructive Pulmonary Disease: Possible Confounding Effect of Treatment Withdrawal? Ann Intern Med, December 18, 2007; 147(12): 882 - 882. [Full Text] [PDF]
|
|
|
|
|
|
A. Qaseem, V. Snow, P. Shekelle, K. Sherif, T. J. Wilt, S. Weinberger, D. K. Owens, and for the Clinical Efficacy Assessment Subcommittee Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline from the American College of Physicians Ann Intern Med, November 6, 2007; 147(9): 633 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wilt, D. Niewoehner, R. MacDonald, and R. L. Kane Management of Stable Chronic Obstructive Pulmonary Disease: A Systematic Review for a Clinical Practice Guideline Ann Intern Med, November 6, 2007; 147(9): 639 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. S. Ko, M. Ip, P. K. S. Chan, M. C. H. Chan, K.-W. To, S. S. S. Ng, S. S. L. Chau, J. W. Tang, and D. S. C. Hui Viral Etiology of Acute Exacerbations of COPD in Hong Kong Chest, September 1, 2007; 132(3): 900 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kardos, M. Wencker, T. Glaab, and C. Vogelmeier Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on Exacerbations in Severe Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., January 15, 2007; 175(2): 144 - 149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W.S. Ko, M. Ip, P. K.S. Chan, J. P.C. Fok, M. C.H. Chan, J. C. Ngai, D. P.S. Chan, and D. S.C. Hui A 1-Year Prospective Study of the Infectious Etiology in Patients Hospitalized With Acute Exacerbations of COPD Chest, January 1, 2007; 131(1): 44 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Heffner Update in pulmonary medicine. Ann Intern Med, November 21, 2006; 145(10): 765 - 773. [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Walker, P. Mitchell, F. Diamantea, C. J. Warburton, and L. Davies Effect of primary-care spirometry on the diagnosis and management of COPD Eur. Respir. J., November 1, 2006; 28(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Ernst and S Suissa Inhaled corticosteroids and mortality in COPD. Thorax, August 1, 2006; 61(8): 735 - 735. [Full Text] [PDF]
|
|
|
|
|
|
I. M. Balfour-Lynn, B. Lees, P. Hall, G. Phillips, M. Khan, M. Flather, J. S. Elborn, and on behalf of the CF WISE (Withdrawal of Inhaled St Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1356 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]
|
|
|
|
|
|
S Scott, P Walker, and P M A Calverley COPD exacerbations {middle dot} 4: Prevention Thorax, May 1, 2006; 61(5): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J van der Palen, E Monninkhof, P van der Valk, S D Sullivan, and D L Veenstra Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease Thorax, January 1, 2006; 61(1): 29 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Marcovitch What's new this month in BMJ Journals BMJ, July 16, 2005; 331(7509): 133 - 133. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
